Stocks
Neurocrine Biosciences (NBIX) EV/EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EV/EBITDA | ? | 42.7 | 25.4 | 35.6 | 40.5 | 29.5 | 16.9 | ||
| Changes by years, y/y, % | -75% | -41% | +40% | +14% | -27% | -29.3% | |||
Neurocrine Biosciences. EV/EBITDA
Neurocrine Biosciences. EV/EBITDA, changes, %
Neurocrine Biosciences (NBIX) EV/EBITDA US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EV/EBITDA | ? | 28.8 | 30.4 | 26.9 | 23.1 | 17.2 | 16.9 | |
| Changes by years, y/y, % | -54% | -26% | -17% | -19% | -40% | |||
| Changes by quarters, q/q, % | +1% | +6% | -12% | -14% | -25% | |||
